Some statistics on transaction value, timing etc. of drugs in development.
With strong neurofilament results, phase 2 trial being prepared and application for orphan drug status most likely post phase 1 trial ... very real possibility IMO.
Also some comments on financial strength of orphan drug status - positives & negatives
Ann: Cohort 3 Pharmacokinetics in MND Patients Completed, page-40
-
- There are more pages in this discussion • 101 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NUZ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.5¢ |
Change
-0.005(2.50%) |
Mkt cap ! $94.89M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 20.3¢ | 19.5¢ | $124.5K | 628.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2791 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 62424 | 2 |
View Market Depth
| Last trade - 15.39pm 01/11/2024 (20 minute delay) ? |
| NUZ (ASX) Chart |